Cochrane · systematic review · CD011492
Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery
Chung, C, Bryant, A, Brown, PD · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
Gynaecological, Neuro-oncology and Orphan CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
13
current version
GRADE rated
8
No studies
5
Included studies
NR
No studies 5 · 38.5%Ungraded 0 · 0%Very low 1 · 7.7%Low 7 · 53.8%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Bevacizumab compared to placebo for the treatment of brain radionecrosis after radiotherapy or radiosurgery
Population: people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a diagnosis of brain radionecrosis based on clinical and radiological criteria
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Reduction in oedema (T2 hyperintensity) Bevacizumab vs placebo | no estimate extracted | 1 study · 14 participants | Low Downgraded: imprecision |
Reduction in post‐gadolinium enhancement Bevacizumab vs placebo | no estimate extracted | 1 study · 14 participants | Low Downgraded: imprecision |
Reduction in neurological/clinical symptoms/severity Bevacizumab vs placebo | no estimate extracted | 1 study · 14 participants | Very low Downgraded: imprecision |
Severe adverse events Bevacizumab vs placebo | no estimate extracted | 1 study · 14 participants | Low Downgraded: imprecision |
Quality of life Bevacizumab vs placebo | no estimate extracted | NR | No studies |
Corticosteroid requirements Bevacizumab vs placebo | no estimate extracted | NR | No studies |
Edaravone plus corticosteroids compared to corticosteroids for the treatment of brain radionecrosis after radiotherapy or radiosurgery
Population: people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a diagnosis of brain radionecrosis based on clinical and radiological criteria
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Reduction in oedema (T2 hyperintensity) Edaravone plus corticosteroids vs corticosteroids | MD 3.03 | 1 study · 137 participants | Low |
Reduction in post‐gadolinium enhancement Edaravone plus corticosteroids vs corticosteroids | MD 0.47 | 1 study · 137 participants | Low |
Improvement in LENT/SOMA Edaravone plus corticosteroids vs corticosteroids | OR 2.51 | 1 study · 137 participants | Low |
Change in neurocognitive function Edaravone plus corticosteroids vs corticosteroids | no estimate extracted | NR | No studies |
Severe adverse events Edaravone plus corticosteroids vs corticosteroids | no estimate extracted | 1 study · 137 participants | Low |
Quality of life Edaravone plus corticosteroids vs corticosteroids | no estimate extracted | NR | No studies |
Corticosteroid requirements Edaravone plus corticosteroids vs corticosteroids | no estimate extracted | NR | No studies |